Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 immunogen: Long-term follow-up

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 11, Issue 4, 1996, Pages 351-364

  Levine, Alexandra M ^a   Groshen, Susan ^a   Allen, Jon ^a   Munson, Katharine M ^a   Carlo, Dennis J ^b   Daigle, Anne E ^b   Ferre, Francois ^b   Jensen, Fred C ^b   Richieri, Steven P ^b   Trauger, Richard J ^b   Parker, John W ^a   Salk, Peter L ^c   Salk, Jonas ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Orchestra Therapeutics Inc   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

AIDS related complex; HIV 1; Hypersensitivity, delayed; Immunotherapy, active

Indexed keywords

ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ZIDOVUDINE;

ACTIVE IMMUNIZATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS INACTIVATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 9244255839     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199604010-00005     Document Type: Article

References (28)

1. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987;327:473-6.
2. Gibbs CJ Jr, Peters R, Gravell M, Johnson BK, Jensen FC, Carlo DJ, Salk J. Observations following HIV immunization and challenge of HIV seropositive and seronegative chimpanzees. Proc Natl Acad Sci USA 1991;88:3348-52.
3. Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis C, Brundage JF, Smith G, Johnson S, Fowler A, Wierzba T, Shafferman A, Volvovitz F, Oster C, Burke DS, Military Medical Consortium for Applied Retroviral Research. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991;324:1677-84.
4. Levine A, Henderson BE, Groshen S, Salk J. Immunization of HIV-infected individuals with inactivated HIV immunogen: significance of HIV-specific cell-mediated immune response [Abst. Th.A337]. Sixth International Conference on AIDS 1990:204.
5. Levine AM, Henderson BE, Groshen S, Peters R, Shepard HW, Salk J. Immunization with inactivated, envelope-depleted HIV immunogen in HIV infected men with ARC: preliminary report of exploratory studies in progress [Abstract]. In: Fifth International Conference on AIDS 1989:219.
6. Getchell JP, Hicks DR, Srinivasan A, Heath JL, York DA, Malonga M, Forthal DN, Mann JM, McCormick JB. Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa. J Infect Dis 1987;156:833-7.
7. LoGrippo GA. Investigations of the use of beta-propiolactone in virus inactivation. Ann NY Acad Sci 1960;83:578-94.
8. Kitchen AD, Mann GF, Harrison JF, Zuckerman AJ. Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins. Vox Sang 1989;56:223-9.
9. Kniker WT, Anderson CT, McBryde JL, Roumniantzeff M, Lesourd B. Multitest CMI for standardized measurement of delayed cutaneous hypersensitivity and cell-mediated immunity: normal values and proposed scoring system for healthy adults in the USA. Allergy 1984;52:75-82.
10. Bollinger RC Jr, Kline RL, Francis HL, Moss MW, Bartlett JG, Quinn TC. Acid dissociation increases the sensitivity of p24 antigen detection for the evaluation of antiviral therapy and disease progression in asymptomatic human immunodeficiency virus-infected persons. J Infect Dis 1992;165:913-6.
11. Nishanian P, Huskins KR, Stehn S, Detels R, Fahey JL. A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals. J Infect Dis 1990;162:21-8.
12. Bishop PC, Boone D, Parker JW. Immunophenotyping by flow cytometry: a longitudinal study in healthy individuals. Diag Clin Immunol 1988;5:232-40.
13. Jackson JB, Coombs RW, Sannerud K, Rhame FS, Balfour HH Jr. Rapid and sensitive viral culture method for human immunodeficiency virus type I. J Clin Microbiol 1988;26:1416-8.
14. Ferre F, Marchese AL, Griffin SL, Daigle AE, Richieri SP, Jensen FC, Carlo DJ. Development and validation of a quantitative PCR assay to assess with precision the amount of HIV-1 DNA in blood cells from patients undergoing a one year immunotherapeutic treatment. AIDS 1993;7(suppl 2): S21-7.
15. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: 1980.
16. Mehta CR, Patel NR. A network algorithm for the exact treatment of Fisher's exact test in R × C contingency tables. J Am Stat Assoc 1983;78:427-34.
17. Wilcoxin F. Individual comparisons by ranking methods. Biometrics Bull 1945;1:80-3.
18. Poulter LW, Seymour GJ, Duke O, Panayi G, Janossy G. Immunohistological analysis of delayed hypersensitivity in man. Cell Immunol 1982;74:358-69.
19. Blatt SP, Hendrix CW, Butzin CA, Freeman TM, Ward WW, Hensley RE, Melcher GP, Donovan DJ, Boswell RN. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med 1993;119:177-84.
20. Frazier TC, Wagner JM, Wray BB, Stafford CT. Multi-test CMI skin test compared with standard intradermal skin testing in evaluation of cell-mediated immunity. J Allergy Clin Immunol 1993;91:213.
21. Schnittman SM, Greenhouse JJ, Pasallidopoulos MC, Baseler M, Salzman NP, Fauci AS, Lane HC. Increasing viral burden in CD4+ cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med 1990;113:438-43.
22. Mathez D, Paul D, De Belilovsky C, Sultan Y, Deleuze J, Gorin I, Saurin W, Decker R, Leibowitch J. Production human immunodeficiency virus infection levels correlate with AIDS-related manifestations in the patient. Proc Natl Acad Sci USA 1990;87:7438-42.
23. Escaich S, Ritter J, Rougier P, Lepot D, Lamelin JP, Sepetjan M, Trepo C. Relevance of the quantitative detection of HIV proviral sequences in PBMC of infected individuals. AIDS Res Hum Retroviruses 1992;8:1833-7.
24. Connor RI, Mohri H, Cao Y, Ho DD. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 1993;67:1772-7.
25. Lu W, Grassi F, Tourani JM, Eme D, Israel-Biet D, Andrieu JM. High concentration of peripheral blood mononuclear cells harboring infectious virus correlates with rapid progression of human immunodeficiency virus type 1-related diseases. J Infect Dis 1993;168:1165-8.
26. Clerici M, Giorgi JV, Chou C, Gudeman V, Zack J, Gupta P, Ho H, Nishanian P, Berzofsky J, Shearer G. Cell mediated immune response to human immunodeficiency virus (HIV) type l in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992;165:1012-9.
27. Shearer BM, Clerici M. T helper cell immune dysfunction in asymptomatic, HIV-1 seropositive individuals: the role of TH1-TH2 cross regulation. Chem Immunol 1992;54:21-43.
28. Salk PL, Salk J. Cell mediated immunologic memory in prevention and treatment of HIV disease. Res Immunol 1994;145:629-35.